AXR Amrep

AMREP Reports Third Quarter Fiscal 2020 Results

AMREP Reports Third Quarter Fiscal 2020 Results

PLYMOUTH MEETING, Pennsylvania, March 09, 2020 (GLOBE NEWSWIRE) -- AMREP Corporation (NYSE: AXR) today reported net income of $338,000, or $0.04 per share, for its 2020 fiscal third quarter ended January 31, 2020 compared to a net loss of $32,000, or $0.00 per share, for the same period of the prior year. For the first nine months of 2020, AMREP had a net loss of $2,027,000, or $0.25 per share, compared to net income of $84,000, or $0.01 per share, for the same period of 2019.

The results of the third quarter of the prior year reflected a net loss from continuing operations of $1,455,000 and net income from discontinued operations of $1,423,000. The first nine months of the prior year reflected a net loss from continuing operations of $2,696,000 and net income from discontinued operations of $2,780,000. Discontinued operations resulted from the sale of AMREP’s fulfillment services business in April 2019.

AMREP Corporation, through its subsidiaries, is a major holder of land and leading developer of real estate in New Mexico.



FINANCIAL HIGHLIGHTS

  Three Months Ended January 31,
   2020  2019 
     
Revenues $  5,287,000  $   2,381,000  
     
Net income (loss) from continuing operations $ 338,000 $ (1,455,000)
       
Net income from discontinued operations  - $   1,423,000 
     
Net income (loss) $   338,000 $ (32,000)
     
Income (loss) per share from continuing operations – Basic and Diluted  $   0.04 $   (0.18 )
     
Income per share from discontinued operations – Basic and Diluted  - $  0.18 
     
Income (loss) per share – Basic and Diluted $   0.04 $  (0.00) 
     
Weighted average number of common shares outstanding - basic    8,138,000    8,103,000 
Weighted average number of common shares outstanding - diluted    8,174,000    8,103,000 
     



  Nine Months Ended January 31,
   2020   2019 
     
Revenues $  14,014,000   $  9,239,000  
     
Net (loss) from continuing operations $   (2,027,000) $  (2,696,000)
     
Net income from discontinued operations  -  $  2,780,000 
     
Net (loss) income $  (2,027,000) $  84,000 
     
(Loss) per share from continuing operations – Basic and Diluted  $  (0.25) $  (0.33)
     
Income per share from discontinued operations – Basic and Diluted  -  $  0.34 
     
(Loss) income per share – Basic and Diluted $  (0.25) $   0.01 
     
Weighted average number of common shares outstanding - basic    8,129,000     8,095,000 
Weighted average number of common shares outstanding - diluted    8,129,000     8,140,000 
     

AMREP Corporation’s financial statements on Form 10-Q are expected to be filed with the Securities and Exchange Commission concurrently with this release and will be available on AMREP’s website (/sec-filings/).

CONTACT: James McMonagle
 Vice President and Chief Financial Officer
 (610) 487-0904



EN
09/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amrep

 PRESS RELEASE

AMREP Reports Third Quarter Fiscal 2025 Results

AMREP Reports Third Quarter Fiscal 2025 Results HAVERTOWN, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- AMREP Corporation (NYSE:AXR) today reported net income of $717,000, or $0.13 per diluted share, for its 2025 fiscal third quarter ended January 31, 2025 compared to net income of $92,000, or $0.02 per diluted share, for the same period of the prior year. For the first nine months of 2025, AMREP had net income of $8,823,000, or $1.64 per diluted share, compared to net income of $2,546,000, or $0.48 per diluted share, for the same period of 2024. Revenues were $7,520,000 and $38,516,000 for th...

Amrep Corp: 1 director

A director at Amrep Corp sold 13,000 shares at 31.558USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

 PRESS RELEASE

AMREP Reports Second Quarter Fiscal 2025 Results

AMREP Reports Second Quarter Fiscal 2025 Results HAVERTOWN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- AMREP Corporation (NYSE:AXR) today reported net income of $4,042,000, or $0.75 per diluted share, for its 2025 fiscal second quarter ended October 31, 2024 compared to net income of $1,108,000, or $0.21 per diluted share, for the same period of the prior year. For the first six months of 2025, AMREP had net income of $8,106,000, or $1.51 per diluted share, compared to net income of $2,454,000, or $0.46 per diluted share, for the same period of 2024. Revenues were $11,906,000 and $30,997,000 ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 19, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 12, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

LUV SOUTHWEST AIRLINES CO.
TTSH TILE SHOP HOLDINGS INC.
MOFG MIDWESTONE FINANCIAL GROUP
MEI METHODE ELECTRONICS INC.
KVHI KVH INDUSTRIES INC.
GDOT GREEN DOT CORPORATION CLASS A
CTRN CITI TRENDS INC.
CRMT AMERICA'S CAR-MART INC.
CODI COMPASS DIVERSIFIED HOLDINGS
CDXS CODEXIS
AHH ARMADA HOFFLER PROPERTIES INC.
NEWT NEWTEK BUSINESS SERVICES INC.
A0JMXQ INDIA CAPITAL GROWTH FUND LTD.
RLMD RELMADA THERAPEUTICS
CULP CULP INC.
EBF ENNIS
APTV APTIV PLC
NANX NANOPHASE TECHNOLOGIES CORP.
AXR AMREP
ETON ETON PHARMACEUTICALS
STIM STIMSONITE CORP
INMB INMUNE BIO
NFE INC.
CAPR NEW FORTRESS ENERGY
EPSN CAPRICOR THERAPEUTICS
FBIO EPSILON ENERGY LIMITED
WSC FABIEN CORP
VRDN WILLSCOT MOBILE MINI HOLDINGS CORP
CTLP VIRIDIAN THERAPEUTICS INC
SMMT CANTALOUPE
PFBX INC.
BMEA SUMMIT THERAPEUTICS INC
FTHY PEOPLES FINANCIAL CORP. (MISSISSIPPI)
ASLE BIOMEA FUSION
BHVN INC.
BIGZ FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND
BUKS AERSALE CORP
ECBK BIOHAVEN LTD
CDIO BLACKROCK INNOVATION AND GROWTH TST
GRNT BUTLER NATIONAL CORP
GTE ECB BANCORP INC.
CRBP CARDIO DIAGNOSTICS HLDGS INC
BMEZ GRANITE RIDGE RESOURCES INC
ASGI GRAN TIERRA ENERGY INC.
SYRS CORBUS PHARMACEUTICALS HOLDINGS INC.
PEO BLACKROCK HEALTH SCIENCES TERM TRUST
XPER ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
OMIC SYROS PHARMACEUTICALS INC.
PMN PETROLEUM & RESOURCES CORPORATION
BNTC XPERI INC
CLNN SINGULAR GENOMICS SYSTEMS INC
BNZI PROMIS NEUROSCIENCES INC.
SIRI BENITEC BIOPHARMA INC
CLENE INC
BANZAI INTERNATIONAL INC
SIRIUS XM HLDGS INC NEW

ResearchPool Subscriptions

Get the most out of your insights

Get in touch